Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-directed phase 2 platform study after progression on first-line osimertinib in advanced non-small cell lung cancer
2018-003974-29Phase 2Active
- Sponsor
- AstraZeneca
- Start
- May 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib, savolitinib, necitumumab, pemetrexed, carboplatin and 8 more in non-small cell lung cancer (NSCLC) (11 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started May 2019; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003974-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003974-29.